Alteration in red cell indices during palbociclib therapy.
03 medical and health sciences
0302 clinical medicine
3. Good health
DOI:
10.1200/jco.2018.36.15_suppl.e13031
Publication Date:
2018-09-05T14:16:49Z
AUTHORS (2)
ABSTRACT
e13031Background: Palbociclib is a CDK 4/6 inhibitor approved for treatment of metastatic hormone receptor positive breast cancer with hormone therapy. We noticed variations in red cell indices in ...
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....